



Risk Management Policy - Summary

Introduction

This document provides a summary of the risk management policy (“**Policy**”) of the group comprising Starpharma Holdings Limited and its controlled entities (collectively “**Starpharma**” or “**Company**”).

The Starpharma Board is committed to a proactive approach in managing material business risks, and aims to ensure that effective risk management practices are a key element of the Company’s culture and in the way activities are carried out at all levels in the Company.

Starpharma operates in a challenging and dynamic environment, and risk management is viewed as integral to realising new opportunities as well as identifying issues that may have an adverse effect on the Company’s existing operations and its sustainability. The Board and management recognise the importance of effective risk management in enabling the Company to fully capitalise on the opportunities available, as well as in mitigating potential loss.

Responsibilities and Authorities

The Policy sets out the allocation of risk management responsibilities and authorities across the following levels of the Company:

- The Board;
- The Audit and Risk Committee;
- The Chief Executive Officer and Chief Financial Officer/Company Secretary;
- The Senior Management Team; and
- All Employees.

Risk Management Approach

Starpharma’s risk management approach includes:

- Strategic Planning – providing a context for risk management within the Company by considering changes to the environment such as legislative changes, business environment, competitor activity, business growth and product development opportunities;
- Risk Profile and Identification – developing and maintaining a profile of risk assessment and control, summarising material risks and actions proposed to effectively manage and control identified risks;
- Risk Analysis – using a range of tools and techniques, including quantitative or qualitative assessment or a combination as applicable;

- Risk Evaluation – to determine whether the level of risk is acceptable or unacceptable and to give priority to risks that have the greatest potential for organisational impact;
- Risk Treatment – applying a hierarchy of control to each risk;
- Monitor and Review – maintaining a risk register summarising all identified material risks, and providing it to the Audit & Risk Committee; and
- Stakeholder Engagement and Communication – informing and consulting with internal and external stakeholders as appropriate in regard to risk assessments, proposed actions or changes to the risk profile.

The Policy identifies areas of risk currently relevant to Starpharma's operations, including, but not limited to the following:

- Strategic
- Operational & Financial
- Legal & Regulatory
- Research & Development
- Product
- Commercial & Intellectual Property
- Health & Safety

Review

The Policy will be reviewed periodically to ensure it continues to comply with applicable laws and regulations and remains relevant and effective.
